C olorectal cancer (CRC) remains a leading cause of cancer-related death, despite major advances in early detection and treatment, primarily because of the metastatic spread of disease. 1 Although sequential mucosal changes, characterized by the accumulation of well-known genetic and epigenetic mutations, lead to the development of a primary CRC, 2,3 the progression to metastatic disease is less well understood. Twenty percent of patients present with metastatic disease (stage IV), and nearly half of all patients diagnosed with stage II and III tumors will develop metastases. 4 Currently, adjuvant chemotherapy is standard for patients with lymph node involvement (stage III), but adjuvant chemotherapy for early stage (I or II) disease is not routine, and stage II patients are selected for chemotherapy based on highrisk clinical and pathologic features. 5 The fact that 20% of stage II patients die of recurrent disease 6 suggests that undetectable pathologic differences exist in tumors that develop metastases. Despite years of gene expression profiling, development of prognostic biomarkers that predict metastatic potential remains elusive. 7 MicroRNAs (miRs) have emerged as valuable biomarkers in cancer because they concurrently target multiple genes in diverse signaling pathways. These small, noncoding RNA molecules function in regulating gene expression 8 and have been found to be dysregulated in CRC, specifically in the progression of disease. 9 Abnormal expression of discrete subsets of miRs (eg, miR-21, miR181a, and miR-200) correlate with advanced tumor stage and metastasis in CRC. [10] [11] [12] [13] Yet, there is no defined miR signature that will consistently predict early and late events in CRC. 7, 13, 14 We posit that an miR expression profile characteristic of metastatic disease may be used to identify a progression of events from early stage to late-stage CRC. Our study aims were to identify an miR signature in metastatic CRC that is associated with the primary tumor and its metastatic site. In addition, we aimed to explore their prognostic potential in a cohort of patients with both earlier and later cancer stages compared with normal tissue and to identify whether those differential miRs marked an early or late event in the development of carcinogenesis.
PATIENTS AND METHODS

Patient Selection
Approval from the institutional review board (No. 4099) was obtained before conducting a review of archived tissue or patient data. Patients with a CRC diagnosis at Oregon Health & Science University (OHSU) and registered in the colorectal tumor registry in conjunction with the OHSU Knight Cancer Institute biorepository were studied. Clinical, pathologic, and outcome data were obtained from medical charts, including age at diagnosis, sex, primary tumor location, American Joint Committee on Cancer stage, presurgical and postsurgical chemotherapy, and radiation treatment. Clinical stage for patients with rectal cancer and pathological stage for patients with colon cancer were classified according to American Joint Committee on Cancer 6 th edition staging manual. Corresponding archived formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples of patients diagnosed with CRC were obtained. All of the tissue samples were selected by our collaborating pathologist for tumor (>50%) and necrosis percentage (<20%).
MiR Array
Fourteen patients were diagnosed with CRC between 2006 and 2012 and were treated with both colon and liver resections at OHSU. All but 1 patient was diagnosed with metastatic disease at initial diagnosis (ie, synchronous diagnosis).
RNA was isolated from FFPE primary colon tumor and liver metastases patient slides using an RNeasy FFPE kit (Qiagen, Hilden, Germany), according to the manufacturer's protocols. The RNA isolation was performed by a single technician to reduce interoperator variation. After isolation, RNA was submitted to the Gene Profiling Shared Resource for RNA quality assessment and microarray assay.
RNA assessment was performed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and both a Nano 6000 and Small RNA Analysis kit (Agilent Technologies). RNA concentration and purity were determined by ultraviolet absorption using a NanoDrop 1000 spectrophotometer (ThermoFisher Scientific, Waltham, MA). Quality assessment was conducted on a total of 48 RNAs. RNA samples of acceptable quality and concentration were labeled. The RNA samples examined had obtained a minimum 260/230 value of 1.0 and a quantity minimum of 50 ng/μL. The majority of the samples had a quantity >50 ng/μL and a quality of 260/230 value closer to 2.0. Genome-wide miRNA expression profiling was performed using an Affymetrix miRNA version 3.0 array (Santa Clara, CA) on 42 samples obtained from 14 patients. The samples were FFPE samples of paired colon tumor, surrounding normal colon tissue, metastatic liver tumor, and surrounding normal liver tissue. There were 7 complete quadruplets (tumor colon, normal colon, tumor liver, and normal liver) and 7 additional pairs of colon and liver tumor samples. The analysis included 3391 miRNA probes (1733 miRNA and 1658 pre-miRNA probe sets) and excluded other small-molecule RNAs (scaRNA, snoRNA, Cdbox, and HAcabox), as well as nonhuman miRNA probe sets.
Raw data files were processed for initial data quality control, and poor performing array assays were eliminated from additional analysis. The final data set and downstream statistical analyses included 42 arrays. Array data were preprocessed and normalized using the Robust Multi-array Average method, perfect match background correction, and quantile normalization, using the Partek Genomics Suite 6.5 software (Partek, Chesterfield, MO). Signal intensities were log2 transformed, and probe set values were summarized using the median polish summarization method.
Data visualization tools (eg, box plot, hierarchical clustering, and multidimensional scaling) were used to assess the general data quality and outliers. To account for within-subject correlations, the mixed-effects model was fit to compare 4 groups for each probe set, assuming a completely unstructured covariance matrix. The 4 groups were: tumor colon (TC), normal colon, tumor liver (TL), and normal liver. The mixed-effects model included all of the available data (n = 42 observations per probe set), accounted within-subject correlations, and performed various comparisons within the same model framework. The following contrast statements were generated to perform specific comparisons: 1) TC versus normal colon, 2) TC versus TL, and 3) TL versus normal liver. The p values from each comparison were adjusted, using the false discovery rate. 15 Probes with false discovery rate p values of ≤0.10 were considered differentially expressed.
MiR Profile Exploration
For the miR profile exploration, tissue samples of normal colon tissue (n = 5), early stage (stage I and II, n = 10), and late-stage (stage III and IV, n = 14) colorectal primary tumors were used for analysis. As above, RNA was isolated from the FFPE patient tissue sample slides, using the RNeasy FFPE kit, and the RNA isolation was performed by a single technician to reduce interoperator variation. RNA was similarly submitted to the OHSU Gene Profiling Shared Resource for RNA quality assessment and quantitation. RNA fragment size distribution below the minimum threshold recommended for sequencing library preparation was excluded.
cDNA synthesis was then performed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) with the TaqMan Small RNA Assay Protocol (Applied Biosystems; with a specific oligo for each miR). Sequences of miR primers used are listed in Supplementary Table (http://links.lww.com/DCR/ A724). Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed with the TaqMan Gene Expression Assays (Applied Biosystems), using the Applied Biosystems ViiA7 qRT-PCR machine. MiR values were normalized to the housekeeping control RNU48.
Target RNA Exploration
Potential targets of the differentially expressed miRs were identified, using OncomiRDB, after a thorough review of publically available miR databases. 16 This database was chosen because of the wider profile of miRs. OncomiRDB identified OLMF4 as a downstream target of miR 486-5p. Protein isolation from paraffin-fixed tissues was limited because of the thickness of the thin tissue sections, and this compromised protein quality because of fixation. Therefore, RNA was isolated from patient samples, and qRT-PCR analysis was performed. OLFM4 expression was explored in the early and late-stage CRC samples using qRT-PCR OLFM4 primers (F:TTTCCAATTTCACCGGCTCC; R:GCTGTGAATTCCAAGCGTTCC).
Basic descriptive statistics were used to describe the patient population of the exploration samples. Relative miR expression was reported using the comparative CT method, as published previously. 17 Characteristics and the distributional properties of the transformed expression values were evaluated for outliers. One outlier was identified and removed. The final sample included the 8-member signature group of miRs from 29 patients. Tests for differences in the miR expression values between groups were conducted using the exact Wilcoxon rank-sum test with the Bonferroni correction for multiple comparisons. Significance for multiple comparisons was set at α = 0.016. For all of the other tests, significance was set at α = 0.05.
RESULTS
A distinct miR signature common in stage IV patientmatched primary CRCs and liver metastases relative to surrounding normal tissue was identified. Patient demographics and treatment factors for tissue used for microarray are described in Table 1 . A cohort of 64 miRs was differentially expressed in primary CRC tissue compared with normal colon tissue. There were an additional 170 miRs differentially expressed in the liver metastatic tissue compared with normal liver tissue. Among the 64 CRC miRs and 170 liver miRs, there were 9 miRs that were commonly expressed in CRC primary tumors and liver metastases (Fig. 1) . A distinct 9-member signature group of miRs was identified as differentially expressed in both stage IV primary CRC, and the corresponding liver metastases relative to surrounding unaffected tissue include miR-18b, miR-93, miR-182, miR-183, miR-21, miR-486-5p, miR-500a, miR-552, and miR-941, as shown in Table 2 (a heat map analysis is shown in Supplementary Figure, http://links.lww.com/DCR/A725). Analysis of the distinct miR profile was performed in a population consisting of normal tissue, early stage CRC (stages I and II), and late-stage CRC (stages III and IV). Expression was compared in late-versus early stage primary CRC tumors, with normal tissue used as the control. Demographic variables, tumor-specific factors, and treatment factors for the validation samples are summarized in Table 3 . In this exploration cohort, miR-486-5p was differentially expressed in early stage CRC compared with normal tissue (p = 0.001). MiR-486-5p was also differentially expressed between late-stage CRC and normal tissue (p < 0.01; Fig. 2 ). The other 8 miRs were not differentially expressed between early and late-stage CRC (Table 4 ). An area under the curve (AUC) was calculated, suggesting that miR-486-5p is highly predictive of early and late-stage CRC (AUC = 0.98, early versus normal; AUC = 0.93, late versus normal).
Pathway analysis was performed using OncomiRDB. This database identified 151 possible downstream targets of mir-486-5p. Of those targets, OLFM4 was a promising downstream target based on previous studies discussed later. We isolated RNA and performed qRT-PCR from patient samples. The target gene OLFM4 was decreased in late-stage CRC relative to early stage disease (Fig. 3) .
DISCUSSION
We have identified a distinct miR signature in patientmatched primary site CRC and metastatic disease that may regulate biologic pathways consistent with an early event in carcinogenesis. In our exploration of this distinct miR 64 9 170
Colon tumorspecific miRs
Common miRs
Liver tumorspecific miRs signature in early and late-stage CRC disease, compared with normal samples, 1 miR was differentially expressed in early stage CRC compared with normal tissue and late-stage compared with normal tissue (miR-486-5p; p < 0.01). Our data suggest that differential expression of this miR in newly diagnosed cancer may herald an early event in colorectal carcinogenesis regulating progression of disease. 9 Bartley et al 9 were the first to describe the phenomenon of early and late patterns of differential miR expression in the adenoma-adenocarcinoma sequence. Early patterns of altered miR expression were noted when significant changes occurred at the first step in the sequence of disease, that is, between normal mucosa and low-grade dysplasia in adenomas. The second major pattern in miRs was not present in low-grade dysplasia. 9 They did not explore early versus late-stage adenocarcinoma miR dysregulation differences. In contrast, we explored advanced-stage miR patterns. We found that miR-486-5p is a herald of early events of expression in colorectal carcinogenesis.
In other cancers, miR-486-5p is associated with attenuated tumor growth and lymphangiogenesis. [18] [19] [20] In gastric cancer specifically, miR486-5p has been closely studied. In a comparison of gastric carcinoma and normal gastric tissues, miR-486-5p was downregulated in gastric cancer cells, similar to our findings in CRC. Using bioinformatics analysis, antiapoptotic glycoprotein OLFM4 was identified as a probable target of miR-486-5p, which was subsequently proven in an in vitro model. When the gene was silenced, proliferation of gastric carcinoma cells in vitro was significantly reduced. This suggests that OLFM4 may be a downstream target of miR-486-5p in CRC. 21 In our exploratory analysis of OLFM4, contrary to gastric cancer studies, we found decreased expression of OLFM4 in late-stage disease but increased expression in early stage disease. This finding may suggest early changes in OLFM4 expression may lead to advanced disease.
Other biologic functions of miR-486-5P have been proposed. One study on miR-486-5p targeted neuropi- lin-2, a gene involved in cardiovascular development. 22 Others have identified its close association with p53, suggesting its role as a tumor-suppressor miR in colorectal cell line SW40. 23 A similar study assessed miR expression of Caco-2 and HCT-116 cell lines. They found a significant increase in expression in miR-486-5p in K-Ras mutated lines, which was confirmed in 25 cancer patient samples. This association likely needs additional assessment, because they did not compare these tissues with normal samples. 24 In contrast, we explored a total of 43 patient samples, including 5 normal and 38 early and late-stage disease samples. We observed a decrease in miR-486-5p expression in early and late-stage disease when compared with normal samples. Therefore, when decreased in primary tumors, as in our populous, cell progression may be unchecked.
On additional exploration of our metastatic miR signature, the remaining miRs were not significantly different; we did, however, note trends in miR-18b, miR-500a, and miR-93. miR-18b has previously been identified in an miR signature that may predict relapse of CRC. 25 Its mechanism is unknown but had been proposed to be a tumor suppressor in melanoma. 26 MiR-500a was decreased in our early stage cohort when compared with normal tissue; there is no understanding, however, of its role in tumorigenesis. MiR-93 was downregulated in early stage disease. MiR-93 expression appears to have a role in the inhibition of CRC, most notably through the suppression of the Wnt/β-catenin signaling pathway, 27 and the inhibition of genes that promote cell growth, migration, proliferation, and angiogenesis. 28 We may not have seen a significant change in these miRs because of our small cohort; they do, however, deserve additional study.
Our results need to be carefully interpreted, because there are small changes in the miR expression in our exploration cohort that may be resolved with a greater number of patients. Additional studies involving a larger array of tissue samples will improve our miR stratification of early and late CRC carcinogenesis. A larger array will elucidate miR expression in the presence and absence of neoadjuvant chemoradiation and differentiate tumor location. Although this study uses a small cohort of patients, the findings suggest that certain miRs are involved in early patterns of disease progression. Additional work is needed to solidify the role of our miRs in conjunction with messenger RNA on carcinogenesis pathways, including OLFM4. Our goal is to continue future studies with a larger cohort of patients with a hope to guide therapeutic efforts at specific events in early carcinogenesis. 
